Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
The profitability profile of the entity demonstrates a cyclical pattern characterized by an initial expansion phase peaking in mid-2022, a subsequent contraction throughout 2023 and early 2024, and a steady recovery period extending through July 2026.
- Gross Profit Margin
- A period of growth is observed from July 2021 (66.53%) to a peak of 67.98% in April 2022. This was followed by a gradual decline, stabilizing within a narrow range between 64.86% and 65.51% from July 2023 through July 2026. This stabilization suggests a normalization of cost of goods sold relative to revenue after a period of volatility.
- Operating Profit Margin
- Operating efficiency improved significantly in the first year, rising from 14.78% to a peak of 19.37% in July 2022. Despite a subsequent dip to 15.82% in April 2024, the margin exhibited a strong recovery trend, ending at 18.08% by July 2026, indicating effective management of operating expenses during the recovery phase.
- Net Profit Margin
- Net profitability exhibited the highest degree of volatility among the margins. After peaking at 16.75% in July 2022, the margin declined to a low of 11.36% in April 2024. A consistent upward trajectory followed, with the margin returning to 13.93% by the end of the period, mirroring the recovery seen in operating margins.
- Return on Equity (ROE) and Return on Assets (ROA)
- Both ROE and ROA show highly correlated movements. ROE peaked at 9.88% in July 2022, declined to a trough of 7.07% in July 2023, and then climbed to a period high of 10.41% by July 2026. Similarly, ROA moved from a peak of 5.79% (July 2022) to a low of 3.99% (July 2023) before recovering to 5.61% in July 2026. The synchronized recovery in these metrics indicates an improvement in overall capital efficiency and asset utilization.
Return on Sales
Return on Investment
Gross Profit Margin
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Gross profit margin = 100
× (Gross profitQ1 2027
+ Gross profitQ4 2026
+ Gross profitQ3 2026
+ Gross profitQ2 2026)
÷ (Net salesQ1 2027
+ Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The gross profit margin exhibited an initial period of growth followed by a gradual compression and a subsequent phase of stabilization. While absolute net sales and gross profit increased over the observed period, the efficiency of converting revenue into gross profit experienced a slight downward shift from its peak levels.
- Margin Expansion and Peak (July 2021 – April 2022)
- An upward trajectory is observed in the first four quarters, with the gross profit margin rising from 66.53% in July 2021 to a peak of 67.98% in April 2022. This phase indicates a period of improved cost management or favorable pricing relative to the cost of goods sold.
- Period of Margin Compression (July 2022 – October 2023)
- Following the peak in April 2022, a steady decline in the margin is evident. The ratio decreased from 67.61% in July 2022 to 65.40% by October 2023. This downward trend suggests that the cost of sales grew at a faster rate than net sales during this period.
- Stabilization and Plateau (January 2024 – July 2026)
- From January 2024 through July 2026, the gross profit margin entered a stabilization phase, consistently fluctuating within a narrow range between 64.86% and 65.51%. During this timeframe, net sales grew significantly, rising from approximately 8.09 billion USD in January 2024 to 9.76 billion USD by July 2026. The fact that the margin remained largely flat despite this increase in volume indicates a consistent cost structure and a lack of further margin expansion.
Operating Profit Margin
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Operating profit | ||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Operating profit margin = 100
× (Operating profitQ1 2027
+ Operating profitQ4 2026
+ Operating profitQ3 2026
+ Operating profitQ2 2026)
÷ (Net salesQ1 2027
+ Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The operating profit margin exhibits a general trajectory of initial expansion, followed by a period of stabilization, a temporary contraction in 2024, and a subsequent recovery. While net sales increased from 7,987 million USD in July 2021 to 9,756 million USD by July 2026, the margin of operating profit did not follow a linear growth path, indicating fluctuations in operational efficiency and cost management over the five-year period.
- Initial Expansion Phase
- A strong upward trend is observed from July 2021 to July 2022, during which the operating profit margin rose from 14.78% to a peak of 19.37%. This period represents the highest level of operational profitability within the analyzed timeframe.
- Stabilization and Moderate Volatility
- Between October 2022 and January 2024, the margin entered a phase of relative stability, generally fluctuating between 17.41% and 19.02%. Despite fluctuations in net sales, the company maintained a consistent ability to convert revenue into operating profit during this interval.
- Significant Margin Compression
- A notable decline occurred in the first half of 2024, with margins dropping to 15.89% in April and reaching a local minimum of 15.82% in July. This contraction suggests an increase in operating expenses or a temporary decline in pricing power relative to costs.
- Recovery and Final Trend
- Starting in October 2024, a consistent recovery trend is evident. The operating profit margin climbed steadily from 16.39% back toward the 18% range, ending the period at 18.08% in July 2026. This recovery coincides with a period of growth in net sales, peaking at 9,808 million USD in April 2026, suggesting that operational efficiencies were restored as the scale of operations increased.
Net Profit Margin
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income attributable to Medtronic | ||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
Net profit margin = 100
× (Net income attributable to MedtronicQ1 2027
+ Net income attributable to MedtronicQ4 2026
+ Net income attributable to MedtronicQ3 2026
+ Net income attributable to MedtronicQ2 2026)
÷ (Net salesQ1 2027
+ Net salesQ4 2026
+ Net salesQ3 2026
+ Net salesQ2 2026)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The net profit margin demonstrates a cyclical trajectory over the observed period, characterized by an initial phase of expansion, a subsequent period of contraction, and a final stage of gradual recovery and stabilization.
- Initial Profitability Expansion (July 2021 – July 2022)
- A consistent upward trend in profitability is observed during this period, with the net profit margin rising from 12.29% to a peak of 16.75%. This growth indicates a significant improvement in the conversion of net sales into profit, reflecting peak operational efficiency within the analyzed timeframe.
- Margin Contraction and Volatility (October 2022 – April 2024)
- Following the July 2022 peak, a period of decline ensued, with the margin reaching a low of 11.36% by April 2024. Despite net sales remaining relatively stable or increasing during parts of this window, net income experienced higher volatility, suggesting that increased operating expenses or external economic pressures compressed profit margins.
- Stabilization and Recovery (July 2024 – July 2026)
- The latter portion of the data shows a sustained recovery. The net profit margin climbed back from the 11% range to stabilize between 13.00% and 13.93%. This recovery coincides with a general increase in net sales, which grew from approximately $8 billion to over $9.7 billion, suggesting that the company regained scale efficiencies and better cost management.
Overall, the correlation between net sales and net income reveals that while revenue growth has been steady over the long term, the net profit margin has been subject to moderate quarterly fluctuations. The trend concludes with an improving profitability profile, ending at 13.93%, which represents a return toward the historical averages seen in early 2022.
Return on Equity (ROE)
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income attributable to Medtronic | ||||||||||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
ROE = 100
× (Net income attributable to MedtronicQ1 2027
+ Net income attributable to MedtronicQ4 2026
+ Net income attributable to MedtronicQ3 2026
+ Net income attributable to MedtronicQ2 2026)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The Return on Equity (ROE) exhibits a cyclical trajectory characterized by an initial period of growth, a mid-term contraction, and a subsequent sustained recovery. The ratio fluctuated between a low of 7.07% and a high of 10.41% over the analyzed period.
- ROE Growth and Contraction Phases
- An upward trend is observed from July 30, 2021, through July 29, 2022, where ROE increased from 7.54% to 9.88%. This growth was followed by a period of decline, reaching a minimum of 7.07% by July 28, 2023. Following this trough, a consistent recovery phase began, culminating in a peak of 10.41% on July 31, 2026.
- Impact of Net Income Volatility
- Net income displayed significant volatility, which directly influenced the ROE fluctuations. A sharp decline in net income to 427 million USD in October 2022 coincided with the start of the ROE downturn. Conversely, the recovery of ROE in the later periods is supported by net income trending upward, reaching 1,470 million USD by July 31, 2026.
- Shareholders' Equity Dynamics
- Shareholders' equity remained relatively stable above 51 billion USD until early 2023. A reduction in the equity base is observed starting in April 2024, with values dipping to approximately 47.9 billion USD. This decrease in equity, paired with rising net income, acted as a catalyst for the acceleration of the ROE toward the end of the period.
The analysis indicates an improvement in the efficiency of generating profits from shareholders' investments. The final quarters of the series demonstrate a strengthened profitability profile, with the ROE reaching its highest level in the final period of the analyzed data.
Return on Assets (ROA)
| Jul 31, 2026 | Apr 24, 2026 | Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income attributable to Medtronic | ||||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-07-31), 10-K (reporting date: 2026-04-24), 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30).
1 Q1 2027 Calculation
ROA = 100
× (Net income attributable to MedtronicQ1 2027
+ Net income attributable to MedtronicQ4 2026
+ Net income attributable to MedtronicQ3 2026
+ Net income attributable to MedtronicQ2 2026)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of profitability ratios over the observed period reveals a cyclical trend in asset utilization efficiency, with the Return on Assets (ROA) experiencing periods of expansion, contraction, and subsequent recovery.
- Return on Assets (ROA) Trend Analysis
- The ROA began at 4.23% in July 2021 and ascended to a peak of 5.79% by July 2022. Following this peak, a downward trajectory was observed, reaching a period low of 3.99% in July 2023. From that point, a consistent recovery phase emerged, with the ratio generally trending upward to finish at 5.61% by July 2026. This indicates a fluctuating but ultimately recovering ability to generate earnings from the total asset base.
- Net Income Volatility
- Fluctuations in ROA are primarily driven by volatility in net income rather than changes in the asset base. Net income exhibited significant variance, with a notable dip to 427 million US dollars in October 2022, which correlates with the sharp decline in ROA during that period. Conversely, the recovery in ROA is mirrored by a return to higher quarterly earnings, peaking at 1,470 million US dollars in July 2026.
- Asset Base Stability
- Total assets remained relatively stable throughout the analyzed timeframe, fluctuating within a narrow band between approximately 89.7 billion and 94.1 billion US dollars. Because the asset base showed minimal variance, the shifts in ROA serve as a direct proxy for operational profitability and bottom-line performance.
- Efficiency Correlation
- A strong positive correlation is observed between net income growth and ROA. The data suggests that the organization's capacity to leverage its assets effectively is highly sensitive to quarterly income swings, as the asset base does not expand or contract significantly in response to these profitability shifts.